Free Trial
NASDAQ:GANX

Gain Therapeutics (GANX) Stock Price, News & Analysis

Gain Therapeutics logo
$1.99 +0.11 (+5.85%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$2.01 +0.02 (+1.21%)
As of 08/29/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Gain Therapeutics Stock (NASDAQ:GANX)

Key Stats

Today's Range
$1.89
$2.02
50-Day Range
$1.44
$1.99
52-Week Range
$0.95
$3.19
Volume
599,362 shs
Average Volume
372,770 shs
Market Capitalization
$71.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.80
Consensus Rating
Buy

Company Overview

Gain Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

GANX MarketRank™: 

Gain Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 669th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Gain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Gain Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Gain Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Gain Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gain Therapeutics is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gain Therapeutics is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Gain Therapeutics has a P/B Ratio of 19.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Gain Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.74% of the float of Gain Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gain Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Gain Therapeutics has recently increased by 22.23%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Gain Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Gain Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.74% of the float of Gain Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gain Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Gain Therapeutics has recently increased by 22.23%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Gain Therapeutics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Gain Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for GANX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Gain Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.18% of the stock of Gain Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 11.97% of the stock of Gain Therapeutics is held by institutions.

  • Read more about Gain Therapeutics' insider trading history.
Receive GANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GANX Stock News Headlines

HC Wainwright Cuts Earnings Estimates for Gain Therapeutics
How “Trump’s New Dollar” Could Impact Your Wealth
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."tc pixel
Gain Therapeutics Reports Q2 2025 Financial Results
See More Headlines

GANX Stock Analysis - Frequently Asked Questions

Gain Therapeutics' stock was trading at $2.16 at the start of the year. Since then, GANX stock has decreased by 7.9% and is now trading at $1.99.

Gain Therapeutics, Inc. (NASDAQ:GANX) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.02.

Gain Therapeutics (GANX) raised $40 million in an initial public offering (IPO) on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager.

Gain Therapeutics' top institutional investors include Geode Capital Management LLC (0.97%) and Marshall Wace LLP (0.92%). Insiders that own company stock include Khalid Islam, Jeffrey Scott Riley, Gene Mack and Matthias Alder.
View institutional ownership trends
.

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gain Therapeutics investors own include PayPal (PYPL), Pfizer (PFE), SEA (SE), Taiwan Semiconductor Manufacturing (TSM), ZIM Integrated Shipping Services (ZIM), ADC Therapeutics (ADCT) and Avino Silver & Gold Mines (ASM).

Company Calendar

Last Earnings
8/12/2025
Today
8/30/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GANX
CIK
1819411
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$6.00
Potential Upside/Downside
+292.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.41 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-289.10%
Return on Assets
-155.11%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
1.79
Quick Ratio
1.79

Sales & Book Value

Annual Sales
$50 thousand
Price / Sales
1,430.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
19.90

Miscellaneous

Outstanding Shares
35,950,000
Free Float
33,368,000
Market Cap
$71.54 million
Optionable
Optionable
Beta
0.10
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:GANX) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners